PMID- 23924943
OWN - NLM
STAT- MEDLINE
DCOM- 20140407
LR  - 20220310
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 14
IP  - 8
DP  - 2013 Aug 6
TI  - Involvement of miR-20a in promoting gastric cancer progression by targeting early 
      growth response 2 (EGR2).
PG  - 16226-39
LID - 10.3390/ijms140816226 [doi]
AB  - Gastric cancer (GC) is one of the most common cancers, with high incidences in 
      East Asia. microRNAs (miRNAs) play essential roles in the carcinogenesis of GC. 
      miR-20a was elevated in GC, while the potential function of miR-20a was poorly 
      understood. miR-20a expression was examined in GC tissues and cell lines. The 
      effects of miR-20a on the growth, migration, invasion, and chemoresistance of GC 
      cells were examined. Luciferase reporter assay and Western blot were used to 
      screen the target of miR-20a. miR-20a was increased in GC tissues and cell lines. 
      miR-20a promoted the growth, migration and invasion of GC cells, enhanced the 
      chemoresistance of GC cells to cisplatin and docetaxel. Luciferase activity and 
      Western blot confirmed that miR-20a negatively regulated EGR2 expression. 
      Overexpression of EGR2 significantly attenuated the oncogenic effect of miR-20a. 
      miR-20a was involved in the carcinogenesis of GC through modulation of the EGR2 
      signaling pathway.
FAU - Li, Xiangsheng
AU  - Li X
AD  - Department of General Surgery, Xinqiao Hospital, Third Military Medical 
      University, Xinqiao Road, Chongqing 400037, China. xiangsonlee@163.com
FAU - Zhang, Zhichao
AU  - Zhang Z
FAU - Yu, Ming
AU  - Yu M
FAU - Li, Liqi
AU  - Li L
FAU - Du, Guangsheng
AU  - Du G
FAU - Xiao, Weidong
AU  - Xiao W
FAU - Yang, Hua
AU  - Yang H
LA  - eng
PT  - Journal Article
DEP - 20130806
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antineoplastic Agents)
RN  - 0 (EGR2 protein, human)
RN  - 0 (Early Growth Response Protein 2)
RN  - 0 (MIRN20a microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Messenger)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Antineoplastic Agents/pharmacology
MH  - Carcinogenesis/*genetics
MH  - Cell Cycle Checkpoints/genetics
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Cell Proliferation
MH  - Cisplatin/pharmacology
MH  - Docetaxel
MH  - Drug Resistance, Neoplasm/genetics
MH  - Early Growth Response Protein 2/biosynthesis/genetics/*metabolism
MH  - Female
MH  - Gene Expression
MH  - Humans
MH  - Male
MH  - MicroRNAs/biosynthesis/genetics/*metabolism
MH  - Neoplasm Invasiveness/genetics
MH  - RNA, Messenger/biosynthesis
MH  - Stomach Neoplasms/*genetics/metabolism
MH  - Taxoids/pharmacology
PMC - PMC3759908
EDAT- 2013/08/09 06:00
MHDA- 2014/04/08 06:00
PMCR- 2013/08/01
CRDT- 2013/08/09 06:00
PHST- 2013/06/05 00:00 [received]
PHST- 2013/07/18 00:00 [revised]
PHST- 2013/07/18 00:00 [accepted]
PHST- 2013/08/09 06:00 [entrez]
PHST- 2013/08/09 06:00 [pubmed]
PHST- 2014/04/08 06:00 [medline]
PHST- 2013/08/01 00:00 [pmc-release]
AID - ijms140816226 [pii]
AID - ijms-14-16226 [pii]
AID - 10.3390/ijms140816226 [doi]
PST - epublish
SO  - Int J Mol Sci. 2013 Aug 6;14(8):16226-39. doi: 10.3390/ijms140816226.